Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (17)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Betriu, C.
Right arrow Articles by Picazo, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Betriu, C.
Right arrow Articles by Picazo, J. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2001) 48, 911-913
© 2001 The British Society for Antimicrobial Chemotherapy

Brief report

Comparative activity of linezolid and other new agents against methicillin-resistant Staphylococcus aureus and teicoplanin-intermediate coagulase-negative staphylococci

Carmen Betriu,*, Montserrat Redondo, Ana Boloix, María Gómez, Esther Culebras and Juan J. Picazo

Department of Clinical Microbiology, Hospital Clínico San Carlos, Plaza Cristo Rey s/n, 28040 Madrid, Spain

The activity of linezolid was determined against 225 recently isolated methicillin-resistant Staphylococcus aureus (MRSA) and 20 methicillin-resistant coagulase-negative staphylococci (CoNS) with decreased levels of susceptibility to teicoplanin. Linezolid activity was compared with other new agents (quinupristin–dalfopristin, trovafloxacin, moxifloxacin, levofloxacin and telithromycin) and six other antimicrobials (erythromycin, clindamycin, gentamicin, vancomycin, teicoplanin and rifampicin). The in vitro activity of linezolid was similar to that of vancomycin. Linezolid inhibited all MRSA strains at between 0.1 and 2 mg/L and all CoNS strains tested at between 0.2 and 0.5 mg/L. These results suggest that linezolid would be useful for the treatment of infections involving these organisms.

* Corresponding author. Tel: +34-91-3303486; Fax: +34-91-3303478; E-mail: cbetriu{at}efd.net


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
N. Kasbekar and P. S. Acharya
Telithromycin: The first ketolide for the treatment of respiratory infections
Am. J. Health Syst. Pharm., May 1, 2005; 62(9): 905 - 916.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
I. Mogenet, S. Raetz-Dillon, J.-M. Canonge, M. Archambaud, and E. Bonnet
Successful Treatment of Staphylococcus epidermidis Hip Prosthesis Infection with Oral Linezolid
Ann. Pharmacother., June 1, 2004; 38(6): 986 - 988.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. Miyazaki, K. Okazaki, M. Tsuji, and K. Yamaguchi
Pharmacodynamics of S-3578, a Novel Cephem, in Murine Lung and Systemic Infection Models
Antimicrob. Agents Chemother., February 1, 2004; 48(2): 378 - 383.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
D. Saralaya, D. G. Peckham, B. Hulme, C. M. Tobin, M. Denton, S. Conway, and C. Etherington
Serum and sputum concentrations following the oral administration of linezolid in adult patients with cystic fibrosis
J. Antimicrob. Chemother., February 1, 2004; 53(2): 325 - 328.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
H. M. Alloush, V. Salisbury, R. J. Lewis, and A. P. MacGowan
Pharmacodynamics of linezolid in a clinical isolate of Streptococcus pneumoniae genetically modified to express lux genes
J. Antimicrob. Chemother., September 1, 2003; 52(3): 511 - 513.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.